Form 4: Shuttle Pharma Director Granted RSUs

Shuttle Pharmaceuticals Holdings, Inc. director Oleh Nabyt was granted 29,240 Restricted Stock Units, vesting over three years.

Summary

• Oleh Nabyt, a Director of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted 29,240 Restricted Stock Units (RSUs).
• Each RSU represents the contingent right to receive one share of common stock.
• The transaction date for the grant was August 8, 2025.
• These RSUs will vest in three equal annual installments, with one-third vesting on August 8, 2026, August 8, 2027, and August 8, 2028.

Sentiment

Score: 5

Explanation: A routine RSU grant to a director is a standard compensation practice and does not inherently indicate positive or negative operational or financial performance. It's a neutral event in terms of immediate company outlook.

Positives

• The grant of Restricted Stock Units to a director aligns their interests with long-term shareholder value, incentivizing performance and retention.

Future Outlook

The vesting schedule indicates future equity distribution to the director over the next three years, aligning their future compensation with company performance.

Industry Context

Granting Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize long-term commitment and align executive interests with shareholder value. This practice is consistent with standard corporate governance and compensation strategies aimed at retaining key talent and fostering growth in a highly competitive sector like pharmaceuticals.

Comparison to Industry Standards

• The grant of 29,240 RSUs to a director is a standard form of equity compensation. While the specific number of units can vary widely based on company size, director responsibilities, and overall compensation philosophy, the use of RSUs with a multi-year vesting schedule is a common mechanism seen in companies like Moderna (MRNA) or BioNTech (BNTX) for their non-executive directors, aiming to foster long-term alignment. Without specific compensation benchmarks for SHPH's peer group or the director's specific role, a direct quantitative comparison is difficult, but the mechanism itself is standard.

Related Party Transactions

• The grant of Restricted Stock Units to Oleh Nabyt, a director, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of RSUs dilutes existing shareholder value over time as shares vest, but it also aims to align the director's interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• Vesting of 9,747 RSUs on August 8, 2026.
• Vesting of 9,747 RSUs on August 8, 2027.
• Vesting of 9,746 RSUs on August 8, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director and does not contain information significant enough to warrant a change in investment recommendation. It's a standard compensation event that aligns director incentives with long-term company performance, but it doesn't provide new insights into the company's operational or financial health that would drive a "buy" or "sell" decision. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Shuttle Pharmaceuticals Holdings Inc., SHPH, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Oleh Nabyt, Equity Grant, SEC Form 4